Clinical Trial Update: Study of BTK Inhibitor, Ibrutinib in Combination With Carfilzomib in Subjects With Relapsed and Refractory Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial updates the combination of ibrutinib with carfilzomib in relapsed/refractory multiple myeloma; status completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Carfilzomib (carfilzomib)
• Ibrutinib (ibrutinib)

Snippet

Sponsor: Pharmacyclics LLC. | Conditions: Multiple Myeloma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2021-12-21